| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer,Svp-r& D | Chief Scientific Officer,Svp-r& D | Sr Vp-research & Development +1 more
1 company
Frederique Ph.D. Menzaghi last filed a Form 4 in February 2024, as Chief Scientific Officer,Svp-r& D at TVRD. Frederique Ph.D. Menzaghi's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Frederique Ph.D. Menzaghi a strong insider score of 85/100, based on 7 past trades. Over a 12-month horizon, all 7 of those trades were profitable, with an average 12-month return of +64.8%.
At the last filing, the largest reported position was 167,247 shares of TVRD. The TVRD filings lean toward selling, a net 283,239 shares.
Frederique Ph.D. Menzaghi has 61 Form 4 filings on record from March 2015 to February 2024, all as Chief Scientific Officer,Svp-r & D at Tvardi Therapeutics (TVRD), 2015–2024.
The 73 reported transactions were 48 open-market sales, 12 stock awards, 9 option or other derivative awards and 4 option exercises.
Counted by filing, the open-market trades come to no purchases and 45 sales worth about $5.0M.
The largest open-market sale was 20,000 shares of TVRD at an average $23.24 on August 1, 2019, about $465K.
1 of the 2 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other was not.
Shares as reported in the last Form 4 for each company; the most recent is from February 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 23, 2023 | TVRD Tvardi Therapeutics, Inc. | Chief Scientific Officer,Svp-r& D | Sell10b5-1 | 2,993 | $3.51 | $10,505.43 | -1.9% | -50.6% | -92.0% | |
| Apr 4, 2023 | TVRD Tvardi Therapeutics, Inc. | Chief Scientific Officer,Svp-r& D | Sell | 2,733 | $4.91 | $13,419.03 | -1.7% | -38.8% | -80.9% | |
| Mar 3, 2023 | TVRD Tvardi Therapeutics, Inc. | Chief Scientific Officer,Svp-r& D | Sell | 6,802 | $9.71 | $66,047.42 | -4.1% | -69.9% | -90.8% | |
| Dec 21, 2022 | TVRD Tvardi Therapeutics, Inc. | Chief Scientific Officer,Svp-r& D | Sell | 3,506 | $11.27 | $39,512.62 | -2.1% | -51.4% | -94.7% | |
| Apr 1, 2022 | TVRD Tvardi Therapeutics, Inc. | Chief Scientific Officer,Svp-r& D | Sell | 1,784 | $11.91 | $21,247.44 | -1.0% | -27.9% | -61.2% | |
| Feb 25, 2022 | TVRD Tvardi Therapeutics, Inc. | Chief Scientific Officer,Svp-r& D | Sell | 2,114 | $10.29 | $21,753.06 | -1.2% | -23.4% | -4.1% | |
| Aug 30, 2021 | TVRD Tvardi Therapeutics, Inc. | Chief Scientific Officer,Svp-r& D | Sell | 3,847 | $14.20 | $54,627.40 | -2.7% | -15.2% | -29.8% | |
| Mar 5, 2021 | TVRD Tvardi Therapeutics, Inc. | Chief Scientific Officer,Svp-r& D | Sell | 3,358 | $17.98 | $60,376.84 | -2.7% | - | - | |
| Feb 25, 2021 | TVRD Tvardi Therapeutics, Inc. | Chief Scientific Officer,Svp-r& D | Sell | 5,003 | $19.33 | $96,707.99 | -4.3% | - | - | |
| Dec 30, 2020 | TVRD Tvardi Therapeutics, Inc. | Chief Scientific Officer,Svp-r& D | Sell | 2,812 | $15.30 | $43,023.60 | -2.5% | - | - |